Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma
NCT04051047Phase 1Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Nov 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine in diffuse midline glioma (DMG), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Number of participants with detectable intratumoral gemcitabine after systemic treatment at Day 1. Planned start Nov 2019; status: withdrawn.
02
Drugs
gemcitabine
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT04051047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04051047.